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ABSTRACT 
The RGD integrins are recognized therapeutic targets for thrombosis, fibrosis, and cancer, 
amongst others. Current inhibitors are designed to mimic the tripeptide sequence (arginine-
glycine-aspartic acid) of the natural ligands; however, the RGD-mimetic antagonists for αIIbβ3 
have been shown to cause partial agonism, leading to the opposite pharmacological effect. The 
challenge of obtaining oral activity and synthetic tractability with RGD-mimetic molecules, 
along with the issues relating to pharmacology, has left integrin-therapeutics in need of a new 
strategy. Recently, a new generation of inhibitor has emerged that lacks the RGD-mimetic. This 
 2 
perspective will discuss the discovery of these non-RGD-mimetic inhibitors, and the progress 
that has been made in this promising new chemotype.  
INTRODUCTION 
Integrins are heterodimeric cell adhesion receptors that mediate the attachment of cells to the 
extracellular matrix (ECM) and are vital in cell to cell interactions.1 These receptors were named 
ÒintegrinsÓ to represent the important role that they play in maintaining the integrity of the 
cytoskeletal-ECM linkage.2 By recognizing binding motifs in ECM proteins and glycoproteins, 
integrins enable adhesion, migration, and proliferation of cells in their biological environment. 
At the time of this review, there are 24 known integrins in humans, each of which is composed of 
two non-covalently associated subunits: an α domain and a β domain (a representative schematic 
of the integrin structure is provided in Figure 1).1 These domains exist solely as dimeric species 
at the cell surface; there is an excess of the β subunit found within the cell, and the availability of 
α subunit counterparts determines the number of receptors that move to the cell surface.3 A study 
by Coller et al. hypothesized that patients with Glanzmann thrombasthenia (a rare bleeding 
disorder) may have a limited availability of β3 subunits, which could account for the low levels 
of αIIbβ3 within the patientsÕ platelets.
4 
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Figure 1. Illustrative representation of an arginine-glycine-aspartic acid (RGD) integrin: α 
domain (blue), β domain (yellow). Based on previously reported structural information.5, 6, 7 
The α domain has a seven-bladed β-propeller at its head, which is supported by the leg structure; 
this is composed of a thigh, a calf-1 (C1), and a calf-2 domain (C2). Similarly, the β domain 
features a βI domain at its head, as well as a hybrid domain (H) and a plexin-sempahorin-integrin 
(PSI) domain. These are supported by a leg consisting of four cysteine-rich epidermal growth 
factor (EGF) repeats, with EGF1 residing in the head domain of some integrins.1 The βI domain 
contains the cations found within the aptly named metal-ion-dependent adhesion site (MIDAS): 
it is at the MIDAS that ligand binding takes place.4 The integrin receptors have flexible 
structures with a number of different conformations; the three main conformations are inactive, 
extended (with either a closed or open headpiece), and ligand occupied (Figure 2), which can be 
recognized by the conformation of the receptor.5  
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Figure 2. RGD integrin conformations: α domain (blue), β domain (yellow), and ligand 
(orange). (a) Bent, inactive; (b) Extended, closed headpiece conformation; (c) Extended, open 
headpiece conformation; (d) Ligand bound, open headpiece conformation. Based on previously 
reported structural information.5, 6, 7 
In the inactive state the integrin is bent over towards the membrane and has a low affinity for 
ligands (Figure 2a); however, when the receptor extends out from the cell surface (Figure 2b), 
and the β H domain undergoes concomitant conformational change (Figure 2c), the receptor is 
primed and thus the integrin is activated. At the time of this review, the accepted paradigm is that 
the inactive integrin has a bent conformation, with the head region pointed towards the 
membrane; however, a report from Choi et al. suggested that in this inactive state the head of the 
receptor was orientated away from the lipid bilayer.9 Further characteristic features of this 
inactive state are the crossing of the transmembrane helices and an cytoplasmic interchain salt 
bridge (Figure 2a).10,11 The conformational changes can be caused by Òinside-outÓ signaling, 
during which proteins within the cell, such as talin and kindlins, bind to the transmembrane base 
of the β domain and induce the change in conformation outside the cell by disrupting the salt 
bridge.1,11-13 Alternatively, Òoutside-inÓ signaling can also result in conformational changes when 
 5 
the integrin ectodomain interacts with a ligand, allowing the cell to sense and react to the 
extracellular environment.12,16 It is in this activated state that the ligands can bind to the open 
headpiece; however, there is evidence that integrins can bind ligands during the bent, or partially 
bent, conformations.14,15 A recent report has shown using biostructural studies of αvβ3 complexes 
with two forms of the physiologic ligand fibronectin, that key π-π interactions between Trp1496 
and Tyr122 of the β3 subdomain may be central to interacting with the inactive integrin without 
inducing any conformational changes in the receptor.16 
The inhibition of integrins can be achieved by preventing the activation of the receptor or by 
blocking the binding site, with the latter being the more common approach.17 Each integrin 
recognizes a specific type of ECM protein, thus the integrin family can be categorized into 
subsets based on the endogenous ligand; (i) leukocyte, (ii) collagen, (iii) RGD, or (iv) laminin 
(Figure 3). The RGD receptors are of particular therapeutic interest, with implications in 
thrombosis, fibrosis, and cancer, among other disease classes.17 Accordingly, this class of 
receptor is, and has been, an active area for the development of novel medicines.  
 
Figure 3. Integrin family, categorized by ligand type. 
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In the 1990s the first successful RGD integrin inhibitors were approved to reduce the risk of 
ischaemic events in patients undergoing percutaneous coronary intervention and those with acute 
coronary syndromes.18 These pioneering inhibitors targeted the platelet αIIbβ3 integrin, also 
known as glycoprotein receptor (GP)-IIb/IIIa, an important target for the prevention of clot 
formation. This receptor is expressed uniquely on the surface of platelets and megakaryocytes, a 
type of platelet-producing cell in the bone marrow.19 The three approved inhibitors are the 
antibody fragment abciximab,20,21 and two small-molecule inhibitors eptifibatide (1),22,23 and 
tirofiban (2)24,25 (for a recent review see King et al.26). Although successful, these intravenously 
administered inhibitors are restricted to high-risk patients. Attempts to develop inhibitors for oral 
dosing were able to overcome the physicochemical challenges allied to zwitterionic compounds 
but there were issues related to pharmacology, with some orally-active antagonists of αIIbβ3 
associated with a 30-35% increase in the risk of death.27,28 Over eight million people have been 
treated using αIIbβ3 antagonists,
29 and to date αIIbβ3 remains to be the only RGD integrin for which 
pharmaceutical agents have been approved. The current clinical progress of selected RGD drugs 
is summarized in Table 1 (for a recent review of integrin-based therapeutics see Ley et al.30).  
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Table 1. Summary of select RGD integrin antagonists. 
Name Structure 
Target 
Integrin(s) 
Therapeutic Target 
(Stage) 
Route of 
delivery 
MWa clogPb 
PSAc 
() 
Abciximab20,21 
(ReoPro) 
Antibody fragment αIIbβ3 Thrombosis 
(Approved) 
Intravenous - - - 
Eptifibatide22,23 
(Integrilin, 1) 
 
αIIbβ3 Thrombosis 
(Approved) 
Intravenous 832 -5.06 328 
Tirofiban24,25 
(Aggrastat, 2) 
 
αIIbβ3 Thrombosis 
(Approved) 
Intravenous 441 0.598 112 
Etaracizumab31,32 Monoclonal antibody αvβ3 Melanoma (Phase II), 
solid tumors (Phase I) 
Intravenous - - - 
MK042933-35 
(L-000845704, 3) 
 
αvβ3 
αvβ5 
Prostate cancer (Phase I), 
Osteoporosis (Phase II) 
Oral 440 -0.307 111 
Cilengitide36-38 (4) 
 
αvβ3 
αvβ5 
α5β1 
 
Glioblastoma (Phase III) Intravenous 589 -3.68 240 
JSM6427à39 (5) 
 
αvβ5 Age-related 
macular 
degeneration 
(Phase I) 
Intravitreal - - - 
Volociximab40,41 Monoclonal antibody α5β1 Solid tumors 
(Phase I) 
Intravenous - - - 
a
Molecular weight (MW); 
b
Calculated logP (clogP); 
c
Topological polar surface area (PSA). Properties determined using JChem for Office 
(Excel).
42 àStructure not disclosed. 
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From consideration of the structures in Table 1, it can be noted that the non-peptide small-
molecule inhibitors still retain RGD mimetics (or KGD) and thus resemble the native ligands of 
these integrins. It is understood that in the binding of the RGD sequence the acid coordinates 
with the Mg2+ and the arginine group resides in a narrow cleft on the β domain forming salt 
bridges with Asp150 and Asp218;6 RGD-mimetic inhibitors, such as Cilengitide (4), are 
designed to make the same interactions as the native ligand (PDB 1L5G, Figure 4). Although 
these zwitterionic peptidomimetics provide potency, they often suffer from sub-optimal in vivo 
pharmacokinetic profiles due to their high molecular weight (MW), high PSA (topological polar 
surface area), low clogP, and, in some cases, high conformational flexibility.  
 
Figure 4. Cocrystal structure of 4 (pink) with αvβ3: α domain (blue), β domain (yellow), Mn
2+ 
ions (green). PDB 1L5G, visualized using PyMOL.43 
Furthermore, the use of oral RGD-mimetic αIIbβ3 inhibitors has led to a major issue in relation to 
pharmacology, as the compounds also have the potential to activate the receptor.44 The approved 
αIIbβ3 inhibitors discussed previously have been reported to also cause partial agonism, resulting 
in the opposite pharmacological effect.45,46 This reported partial agonism is a result of allosteric 
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changes upon binding, which prime the receptor. A preclinical study by Reynold et al. found that 
the αvβ3 antagonist cilengitide may promote tumor growth in vitro;
47 however, these results are 
highly debated, with many clinical trials of cilengitide indicating no safety signal.48  
One RGD-mimetic small molecule antagonist of αIIbβ3 that does not induce receptor priming 
upon binding is UR-2922 (6), which is the active form of the prodrug UR-3216 (7) (Figure 5). 
49,50 This antagonist (6), developed by Ube, has been shown to bind tightly to resting platelets, 
with a Ki of <1 nM. The excellent potency, along with a favorable pharmacokinetic profile, is 
advantageous for oral dosing of this antagonist. Although 6 has the RGD-mimetic of the typical 
RGD integrin antagonist, no partial agonism of the αIIbβ3 receptor has been reported as a result of 
it binding. Modelling studies carried out by Cox et al. suggested that this analogue does not 
interact with the MIDAS, and thus does not activate the receptor.17 Instead of interacting with the 
cation, the authors propose that the carboxyl group of 6 forms an H-bond with Tyr166 and a salt 
bridge with Arg165. This proposed alternative binding of the acidic motif, along with additional 
π-π interactions with Phe160, would distinguish this RGD-mimetic inhibitor from the 
compounds described in Table 1; however, it is surprising that an RGD-mimetic inhibitor would 
bind via an alternative binding mode, and no biostructural evidence was reported to support the 
authorÕs hypothesis.  
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Figure 5. αIIbβ3 antagonist 6 and the prodrug form 7. IC50 for inhibition of ADP-induced 
aggregation of platelets (human).49,50  
A potential approach to avoid this unwanted activation of αIIbβ3 is to design inhibitors that block 
the binding site without forming the interactions made by the native RGD sequence. Thus the 
design of non-RGD-mimetic inhibitors could identify effective small-molecule antagonists that 
do not activate the integrin. This is a particularly promising strategy for integrin therapeutics 
targeting the RGD subfamily as the increase in mortality associated with the oral αIIbβ3 
antagonists has been attributed to the ability of RGD-mimetic inhibitors to prime the receptor.27,28 
Furthermore, the development of non-RGD-mimetic inhibitors could lead to a more synthetically 
tractable series, that could provide easier explorations of SAR. By avoiding the RGD-mimetic, 
compounds may also have the potential to possess more favorable physicochemical properties, 
and therefore improved pharmacokinetic profiles.  
αIIbβ3 NON-RGD-MIMETIC INHIBITORS 
The first non-RGD-mimetic inhibitor of αIIbβ3 was identified in 2008 by Blue et al. using a 
medium throughput screen (MTS) of 33,264 small molecules.51 This inhibitor, termed RUC-1 (8, 
IC50 = 9.7 ±1 µM),
51 was reported to be effective and selective at αIIbβ3, with no activity observed 
at the related integrin αvβ3, Figure 7. Through docking studies, 8 was determined to interact only 
7 (UR-3216)
MW: 564; clogP: 1.45; PSA: 195 
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with the αIIb domain and not with the β3 subunit, thus explaining the specificity over αvβ3 
displayed by this inhibitor. The authors also reported that this compound did not show any 
agonism of the integrin and hypothesized that the lack of interactions with the MIDAS metal ion 
may be the reason for this. Mutagenesis studies were carried out which supported the proposed 
binding mode.52 Subsequently, the cocrystal structure of 8 with αIIbβ3 confirmed that the binding 
site was localized to the αIIb domain and provided further insight into this small molecule 
inhibitor.53 This crystal structure revealed that 8 binds to the closed conformation of the integrin 
headpiece and does not result in any priming of the receptor (PDB 3NIF). This is in contrast to 
RGD-mimetic antagonists, which have been shown to activate αIIbβ3 resulting in partial 
agonism.44,45 The Coller group were able to develop 8 further, through structure-based design, 
and produce an analogue with approximately 100-fold higher affinity, termed RUC-2 (9, IC50 = 
95 ±5 nM).54  This more potent analogue was soaked into crystals of the αIIbβ3 headpiece, but no 
density for the metal ion at the MIDAS was observed (PDB 3T3M, Figure 6).54 It was noted that 
9 had the same binding interactions as 8 but with additional interactions in the β3 βI domain. The 
primary amine of 9 was discovered to compete with the Mg2+ for interactions with the carboxyl 
oxygen of Glu220; thus, in high enough concentration, 9 displaced the metal ion of the MIDAS, 
explaining its absence from the crystal structure.  
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Figure 6. 9 (pink) bound within αIIbβ3: α domain (blue), β domain (yellow). PDB 3T3M, 
visualized using PyMOL.43 
Furthermore, the authors report that 9 does not activate the integrin upon binding, thus 
preventing any unwanted signaling. This compound is the first in a novel class of integrin 
antagonists termed Òion displacement ligandsÓ by the developers of 9.55 In 2014 the Coller group 
reported the SAR surrounding the optimization of 9. Two analogues were disclosed: RUC-3 (10) 
and RUC-4 (11),55 and the results of their docking studies compared with the binding of 9 
suggested that additional water-mediated interactions of the nitrogen atoms with the receptor 
were responsible for the differences in the potencies observed, Figure 7. Unfortunately, 10 was 
found to be unstable in solution (DMSO or aqueous), and as a result was deprioritized. Through 
the ADMET profiling of 9 and 11, it was found that 11 had a modest microsomal stability profile 
(23.2 µL/min/mg, human) whereas 9 was highly resistant (-1.16 µL/min/mg, human). 
Incorporation of a nitrogen into the aromatic ring at the core to give 11 increased the aqueous 
solubility (thermodynamic solubility at pH 7.4: 9 28.0 µg/mL; 11 239.5 µg/mL) and maintained 
the potency. This chemotype was recently patented,56 and further research is underway for the 
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development of the more water soluble 11 towards a pre-hospital treatment of myocardial 
infraction.57  
 
Figure 7. RUC-1 (8),51 RUC-2 (9),54 RUC-3 (10), and RUC-4 (11)55 from the Coller group. IC50 
for inhibition of ADP-induced aggregation of platelets (human).  
Based on the unique binding mode of 8 and 9, Negri et al. carried out a structure-based virtual 
screen with the aim of identifying new small molecule antagonists of αIIbβ3.
58 Over 2.5 million 
Òlead-likeÓ compounds of the ZINC database59 were screened, and then five potential antagonists 
were selected from the top 500 scoring compounds. The ligands were selected based on the 
interactions observed during modelling, diversity of chemotype, and their commercial 
availability. Of the 5 compounds purchased (termed MSSM-1-5), four were successfully tested 
for biological activity against αIIbβ3, and two were found to show micromolar inhibition of αIIbβ3, 
including MSSM-1 (12),58 Figure 8. These novel inhibitors were also found to show specificity 
for their desired integrin over αvβ3, and no undesired priming of the receptor was observed. In 
2015 a second virtual screen of antagonists for αIIbβ3 was reported by Wang et al.
60 This work 
combined the structure-based in silico screen with a ligand-based pharmacophore screen of over 
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7.3 million Òdrug-likeÓ compounds from the ZINC database. Their campaign identified 11 
commercially available compounds, which were obtained and tested for their inhibitory effect 
against platelet aggregation. Three compounds were found to exhibit micromolar activity, with 
compound 1360 displaying the highest potency, Figure 8. Wang et al. also comment that this 
potential antagonist is predicted to have good solubility, permeability, ADMET properties, and 
low toxicity in vivo. This is perhaps surprising as the basic 4-aminopyridine motif will increase 
the polarity of 13, thus lowering the permeability of this inhibitor; however, no measured 
permeability or pharmacokinetics were reported. With few non-RGD-mimetic inhibitors known 
in the literature, broad in silico screening appears to be a valuable tool for identifying novel 
scaffolds, but it is limited by the database(s) used.  
 
Figure 8. αIIbβ3 inhibitors identified by virtual screening. IC50 for inhibition of ADP-induced 
aggregation of platelets (human).58,60 Stereochemistry of 13 not reported. 
A more recent report from Polishchuk et al. used quantitative structureÐactivity relationship 
(QSAR) and pharmacophore models to screen a number of databases for novel αIIbβ3 antagonists, 
but no hit compounds were identified.61 The authors concluded that this was the result of the low 
number of zwitterionic compounds available in the commercial libraries used for their screen. 
Thus, the group used their models to design focused libraries of novel compounds, which were 
screened to identify ligands that could bind either the open or the closed form of the αIIbβ3 
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receptor. In order to model ligands for the open form, the RGD-mimetic inhibitor Tirofiban was 
used, whereas the closed form analogues were based on 9. The virtual hit compounds were 
synthesized and through biological screening, one low nanomolar inhibitor for the closed 
receptor was successfully identified (compound 14).61 Docking studies carried out using 
compound 14 showed a similar binding mode to that of 9, but this analogue showed superior 
levels of potency with an IC50 of 11 nM, Figure 9. A key feature of their model for a closed form 
binder was a distance of 15.8  between two positively charged centers. The authors later 
confirmed this hypothesis using a series of analogues in which this distance was varied.62 This 
study showed that shortening the compound by one carbon (compound 15) caused a greater than 
100-fold decrease in potency, and lengthening by one carbon (compound 16) was also 
unfavorable, resulting in micromolar inhibition, Figure 9.  
 
Figure 9. αIIbβ3 non-RGD-mimetic inhibitors designed from 9. IC50 for inhibition of ADP-
induced aggregation of platelets (human).61,62  
αvβ3 NON-RGD-MIMETIC INHIBITORS 
To the best of our knowledge, the first example of a non-RGD-mimetic inhibitor of an RGD 
integrin was reported by Dayma et al. in 2006.63 This work utilized common feature 
pharmacophore models, which were derived from known αvβ3 inhibitors. Two databases were 
screened (NCI2000 and Chemical Diversity) using the pharmacophore model, to give over 400 
HN
NN
HN
O
N
H
O
NH2
14, n = 2, IC50 = 11 ±1 nM; MW: 316; clogP: -0.95; PSA: 118 
15, n = 1,  IC50 = 150 ±25 nM; MW: 302; clogP: -1.19; PSA: 118 
16, n = 3, IC50 = 1.4 ±0.17 µM; MW: 330; clogP: -0.91; PSA: 118 
n
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compounds. Hit compounds were then filtered by physicochemical properties, structural 
diversity, and commercially availability, to give 29 potential antagonists, which were obtained 
for further investigation. Through in vitro evaluation, four compounds were found to inhibit 
αvβ3, including the non-RGD-mimetic compound 17,
63 Figure 10. The authors recognized the 
novelty of this inhibitor and carried out a small SAR study, which identified inhibitor 1863 with 
an 800-fold higher affinity than the initial hit 17. This subnanomolar non-RGD-mimetic αvβ3 
inhibitor was shown to have low cytotoxicity, and therefore the authors suggest this inhibitor has 
potential for the development of a noncytotoxic anticancer therapy. The 2-imino-rhodanine 
motifs at the core of 17 and 18 are often identified as screening hits, and thus are recognized pan-
assay interference compounds (PAINS); therefore, these inhibitors may be unsuitable for further 
development.64 
 
Figure 10. αvβ3 inhibitors identified by Dayam et al. IC50 for inhibition of αvβ3 receptor binding 
assay.63 
This work was closely followed by a report from Zhou et al. in which a number of small 
molecule inhibitors of αvβ3 that lacked the aspartic acid mimetic were discovered.
65 By using a 
crystal structure of αvβ3 in complex with an RGD ligand (PDB 1L5G, Xiong et al.
6), this group 
carried out a virtual screen of 88,695 commercially available organic compounds. A rigorous 
triage of docking results was used to successfully identify 50 potential inhibitors for biological 
testing. From the compounds that were selected for testing, seven were found to have inhibitory 
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activity with an IC50 of <200 µM. The most potent of the hit compounds was inhibitor 19
65 with 
an IC50 = 38.5 ±1.7 µM, which was progressed onto further testing in vitro and found to 
effectively inhibit cell migration and angiogenesis, Figure 11. Zhou et al. went on to explore this 
non-RGD-mimetic small molecule further through the synthesis of a series of analogues, which 
led to the identification of another inhibitor of similar potency, compound 20 (IC50 = 33.5 ±3.1 
µM),65 Figure 11. Docking studies of this compound identified that, in the most energetically 
favorable binding pose, the biguanide group can interact with a number of residues in the 
MIDAS through a series of H-bonds. This predicts that inhibitors of this chemotype will interact 
with the receptor through a significantly different binding mode than that of the more classic 
RGD-mimetic inhibitors, which is surprising as the biguanide might be expected to mimic the 
arginine. Unfortunately, no further structural information was obtained, and thus the alternative 
binding mode of these compounds remains unconfirmed. The authors do not report whether these 
non-RGD-mimetic compounds are both antagonists and/or partial agonists of the receptor; 
nevertheless, both inhibitor 19 and 20 having the low molecular weight of 246 Da makes the 
ligand efficiency of these compounds high. 
 
Figure 11. αvβ3 inhibitors identified by Zhou et al. IC50 for inhibition of αvβ3-mediated cell 
adhesion.65 
Another series of small molecule non-RGD-mimetic αvβ3 inhibitors was reported by Elliot et al. 
in 2009.66 This group had taken an alternative strategy and designed a series of novel inhibitors 
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without the arginine motif. Their approach began with the screening of low molecular weight 
carboxylic acids and acid isosteres, from which they identified the hit compound 21,66 Figure 12. 
This initial hit had a promising IC50 of 800 nM, thus demonstrating that it is possible to achieve 
good affinity with αvβ3 using a non-RGD-mimetic chemotype, but the authors do not report any 
details of the assay used. Through exploration of the SAR, Elliot et al. were able to improve this 
potency with the development of lead compound 22 with an IC50 of 11 nM;
66 however, the 
compound had limited permeability (parallel artificial membrane permeability assay (PAMPA) = 
0.021 x 106 cm s-1) and the authors comment that there was only modest selectivity for αvβ3 over 
αIIbβ3. Based on analysis of previously reported crystal structures of these two integrins (PDB 
1L5G vs. 1TY7) and modelling studies, the authors hypothesized that altering the ortho position 
of the sulfonamide could improve the selectivity. Through the synthesis of further ortho 
substituted analogues compound 2366 was discovered, with an IC50 of 700 nM and a >130-fold 
selectivity for their desired target αvβ3 over αIIbβ3. This work shows that it is possible to design 
nanomolar inhibitors of αvβ3 without the use of an RGD-mimetic, although the PSA values of 
these inhibitors are high.  
 
Figure 12. αvβ3 inhibitors identified by Elliot et al.
66 Assay protocol not reported.  
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α5β1 NON-RGD-MIMETIC INHIBITORS 
In 2007, a patent by AstraZeneca was reported claiming a series of small molecule inhibitors of 
the RGD integrin α5β1.
67 The majority of compounds covered by the patent had the RGD-
mimetics, but there were a small number of inhibitors claimed that did not fit this chemotype; for 
example, compound 2467 which lacks the arginine mimetic, Figure 13. This inhibitor was 
reported to have an IC50 of 4 µM in a cell adhesion assay and an IC50 of 466 nM using a second 
electrochemiluminescence ligand binding assay. Thus showing that this compound was able to 
inhibit α5β1 in vitro, however, no in vivo data was reported. Although 24 is a non-RGD-mimetic 
inhibitor, this compound is quite large and lipophilic, with the high MW of 545 Da and high 
clogP of 5.44. Based on these physicochemical properties 24 might be predicted to suffer from 
poor ADMET; however, no measured pharmacokinetics were disclosed.  
 
Figure 13. α5β1 inhibitor 24 reported by AstraZeneca.
67 aElectrochemiluminescence ligand 
binding assay. bCell adhesion assay.  
More recently, another non-RGD-mimetic inhibitor of α5β1 was reported by Kang and Kim.
68 
Termed IPS-05002, compound 2568 was identified by a screen of a phytochemical compound 
library using a ProteoChip-based protein-protein interaction assay for α5β1 antagonists. This 
compound showed micromolar inhibition of α5β1 in a cell proliferation assay and a cell migration 
assay, Figure 14. Furthermore, the authors report that this antagonist inhibits cell adhesion and 
24
IC50 = 466 nM
a; IC50 = 4 µM
b
MW: 545; clogP: 5.44; PSA: 99 
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tubular network formation, and thus 25 may inhibit angiogenesis. This experimental evidence 
shows the potential for this novel small molecule to be developed into a potent antagonist; 
however, the complex structure may limit an SAR exploration of this scaffold if the synthetic 
route is not amenable to diversification.  
 
Figure 14. α5β1 inhibitor 25.
68 aCell proliferation assay. bCell migration assay. Stereochemistry of 
25 not reported. 
In summary, the RGD integrins are recognized therapeutic targets.  Numerous RGD inhibitors 
have been evaluated clinically for a range of therapeutic indications.  For example αvβ3/αvβ5 
inhibitor cilengitide alone has been studied in at least 35 clinical trials with issues appearing to 
be efficacy rather than safety.  To date however, inhibitors have been approved for only one 
integrin from this class namely intravenous αIIbβ3.  Safety issues were seen with oral αIIbβ3 
inhibitors and ascribed to conformational changes in the receptor upon binding. The emergence 
of small molecule non-RGD-mimetic inhibitors has led to the discovery of new chemotypes with 
the promise of much increased synthetic tractability, which inhibit the RGD integrins, without - 
in the case of αIIbβ3 - the activation of the receptor, but the development of an efficacious, safe 
drug from this new generation of inhibitors is yet to be achieved. Initial compounds were 
identified using MTS and virtual screening; however, biostructural information on the non-RGD-
mimetic inhibitors bound to the receptor, along with advancements in the understanding of the 
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unwanted integrin priming, has provided clues to the rational design of novel non-RGD-mimetic 
compounds. This new generation of RGD-integrin antagonists could lead to the development of a 
safe and efficacious oral dosing αIIbβ3 inhibitor, and help realize the potential of the RGD 
integrins as therapeutic targets.  
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